Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures
- PMID: 11600360
- PMCID: PMC90786
- DOI: 10.1128/AAC.45.11.3084-3091.2001
Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures
Abstract
A survey of 1,203 Escherichia coli isolates from 44 hospitals in Taiwan revealed that 136 (11.3%) isolates were resistant to fluoroquinolones and that another 261 (21.7%) isolates had reduced susceptibility. Resistance was more common in isolates responsible for hospital-acquired (mostly in intensive care units) infections (17.5%) than in other adult inpatient (11.4%; P = 0.08) and outpatient isolates (11.9%; P > 0.1). Similarly, reduced susceptibility was more common in isolates responsible for hospital-acquired infections (30.9%) than in other adult inpatient (21.0%; P = 0.04) and outpatient (21.4%; P = 0.06) isolates. Isolates from pediatric patients were less likely to be resistant (1.3 versus 12.0%; P < 0.01) but were nearly as likely to have reduced susceptibility (17.7 versus 21.9%; P > 0.1) as nonpediatric isolates. There was an inverse relationship in the proportion of isolates that were resistant versus the proportion that had reduced susceptibility among isolates from individual hospitals (R = 0.031; P < 0.05). In an analysis of isolates from two hospitals, all 9 resistant strains possessed double point mutations in gyrA and all 19 strains with reduced susceptibility strains had single point mutations; no mutations were found among fully susceptible strains. Risk factors for resistance included underlying cancer (odds ratio [OR], 83; 95% confidence interval [CI(95)], 7.3 to 2,241; P < 0.001), exposure to a quinolone (OR, undefined; P = 0.02), and exposure to a nonquinolone antibiotic (OR, 20; CI(95), 2.2 to 482; P < 0.001); underlying cancer was the only independent risk factor (OR, 83; CI(95), 8.6 to 807; P < 0.001). There were no significant associations between any of these factors and reduced susceptibility. Whereas acute and chronic quinolone use in cancer patients is a major selective pressure for resistance, other undetermined but distinct selective pressures appear to be more responsible for reduced susceptibility to fluoroquinolones in E. coli.
Figures


Similar articles
-
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.Microb Drug Resist. 2001 Spring;7(1):47-53. doi: 10.1089/107662901750152783. Microb Drug Resist. 2001. PMID: 11310803
-
Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative.J Infect Dis. 2006 Jul 1;194(1):79-85. doi: 10.1086/503046. Epub 2006 May 31. J Infect Dis. 2006. PMID: 16741885
-
Quinolone resistance among Escherichia coli strains from community-acquired urinary tract infections in Greece.Clin Microbiol Infect. 2004 Jan;10(1):75-8. doi: 10.1111/j.1469-0691.2004.00807.x. Clin Microbiol Infect. 2004. PMID: 14706091
-
Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.Int J Antimicrob Agents. 2010 Jan;35(1):76-9. doi: 10.1016/j.ijantimicag.2009.08.003. Epub 2009 Sep 24. Int J Antimicrob Agents. 2010. PMID: 19781915
-
Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.J Microbiol. 2005 Oct;43(5):391-7. J Microbiol. 2005. PMID: 16273029
Cited by
-
Amino acid substitutions in GyrA of Burkholderia glumae are implicated in not only oxolinic acid resistance but also fitness on rice plants.Appl Environ Microbiol. 2007 Feb;73(4):1114-9. doi: 10.1128/AEM.02400-06. Epub 2006 Dec 28. Appl Environ Microbiol. 2007. PMID: 17194844 Free PMC article.
-
Pathogenic potential and the role of clones and plasmids in beta-lactamase-producing E. coli from chicken faeces in Vietnam.BMC Vet Res. 2019 Apr 4;15(1):106. doi: 10.1186/s12917-019-1849-1. BMC Vet Res. 2019. PMID: 30947723 Free PMC article.
-
Hygiene of Medical Devices and Minimum Inhibitory Concentrations for Alcohol-Based and QAC Disinfectants among Isolates from Physical Therapy Departments.Int J Environ Res Public Health. 2022 Nov 9;19(22):14690. doi: 10.3390/ijerph192214690. Int J Environ Res Public Health. 2022. PMID: 36429408 Free PMC article.
-
Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997-2007.Infection. 2009 Dec;37(6):534-9. doi: 10.1007/s15010-009-8457-0. Infection. 2009. PMID: 20013094
-
Prevalence of antimicrobial resistance and potential pathogenicity, and possible spread of third generation cephalosporin resistance, in Escherichia coli isolated from healthy chicken farms in the region of Dakar, Senegal.PLoS One. 2019 Mar 26;14(3):e0214304. doi: 10.1371/journal.pone.0214304. eCollection 2019. PLoS One. 2019. PMID: 30913237 Free PMC article.
References
-
- Anonymous. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: a report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control. 1999;27:279–284. - PubMed
-
- Blazquez R, Menasalvas A, Carpena I, Ramirez C, Guerrero C, Moreno S. Invasive disease caused by ciprofloxacin-resistant uropathogenic Escherichia coli. Eur J Clin Microbiol Infect Dis. 1999;18:503–505. - PubMed
-
- Canawati H N, el Farra R, Seymour J, Shimashita J, Dunn D, Montgomerie J Z. Ciprofloxacin-resistant Escherichia coli emerging in a rehabilitation medical center. Diagn Microbiol Infect Dis. 1997;29:133–138. - PubMed
-
- Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995;20:557–560. - PubMed
-
- Conrad S, Oethinger M, Kaifel K, Klotz G, Marre R, Kern W V. gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. J Antimicrob Chemother. 1996;38:443–455. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical